Maraviroc.
Maraviroc, first in a new pharmacological class of antiretroviral agents known as CCR5 antagonists, has been approved by the U.S. Food and Drug Administration for the treatment of HIV-infected adult patients who are infected with only CCR5-tropic HIV-1 virus and who have HIV-1 strains resistant to multiple antiretroviral agents. Maraviroc has demonstrated in vitro activity against a wide range of CCR5 tropic clinical isolates, including those resistant to the four currently existing drug classes of antiretroviral agents. In the two pivotal phase III studies, MOTIVATE-1 and -2, maraviroc, in combination with optimized background therapy (OBT), demonstrated superior virologic and immunologic treatment outcomes than OBT alone in treatment-experienced patients infected with CCR5-tropic HIV-1. In these studies, maraviroc also demonstrated acceptable safety and tolerability profiles with adverse events and discontinuation rates in general comparable to those noted in the placebo arms.
Fadel
Hind
H
Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Temesgen
Zelalem
Z
D000818:Animals; D018849:Controlled Clinical Trials as Topic; D003510:Cyclohexanes / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D005260:Female; D018565:Food-Drug Interactions; D023581:HIV Fusion Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D008297:Male; D000077592:Maraviroc; D014230:Triazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D014230:Triazoles; D000077592:Maraviroc